Navigation Links
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Date:3/18/2009

SAN FRANCISCO, March 18 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has received written permission from the U.S. Food and Drug Administration (FDA) to begin a pivotal Phase 3 trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed docetaxel-based chemotherapy. The placebo-controlled, double-blind, multinational trial will enroll approximately 1,200 patients who will be randomized (2:1) to receive either MDV3100 or placebo. The primary endpoint of the trial will be overall survival.

"This is a significant milestone in the development of this important novel investigational drug," said David T. Hung, M.D., president and chief executive officer of Medivation. "We look forward to starting the trial and rapidly executing a comprehensive Phase 3 development program for MDV3100. Given the encouraging results seen to date in our ongoing Phase 1-2 trial and the limited life expectancy of men with CRPC who have failed chemotherapy, we will work to begin the Phase 3 clinical development of MDV3100 as quickly as possible this year."

The FDA informed the Company that it could test a dose of MDV3100 up to 240mg/day. There are no driving or other restrictions placed on the activities of participants in the trial. Final trial specifics will be announced when the first patient is enrolled.

MDV3100 Ongoing Phase 1-2 Trial

MDV3100 is being evaluated in an ongoing open-label, U.S., Phase 1-2 study of a total of 140 men with CRPC. Patients in this trial were heavily pretreated, with all having failed standard hormonal therapies and many having also failed docetaxel-based chemotherapy. MDV3100 has consistently demonstrated encouraging anti-tumor activity across dose levels and endpoints
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
2. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
5. Medivation Announces Participation in Upcoming Conferences
6. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
7. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
8. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
9. Urban Health Plan Receives $1.3M from Economic Stimulus Package to Increase Health Care Access in Corona, Queens
10. CUREXO Technology Corporation Receives Quality Certificate
11. Silk Information Systemss Silk V 4.2 Receives 08 CCHIT Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... As reported by the Frederick News Post in the ... (8/17), a graduate of the Frederick County Drug Treatment Court has ... with the program. The graduate, Korey Shorb, put together a race ... walk. He plans to donate the proceeds of the event to ... helped him. Shorb, who graduated in 2008, admitted that he would ...
(Date:8/29/2014)... 30, 2014 Market Research Report ... is a professional and in-depth market survey on ... firstly reviews the basic information of Glass microfiber ... report then explores global and China’s top manufacturers ... Production value, and market share etc. , The ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... G. Rodas. Dr. Rodas will be practicing out of ... As a member of Healthpointe’s orthopedic team, ... internal medicine, and board-certified in occupational medicine. , ... title as Medical Director of Raytheon, the world-class defense ...
(Date:8/29/2014)... 2014 Dr. Parsa Mohebi M.D. has developed ... loss achieve great results in hair transplantation. One of ... , an FUE method that harvests facial hair for transplanting ... lets patients whose hair loss classification is 5 and above ... a great alternative for those advanced hair loss patients who ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe ... Chapman University Physical Therapy students via Clinical Rotations. ... University will be shadowing Healthpointe providers and specialists ... them to develop clinical experience and learn professional ... students will gain insight into several patient care ...
Breaking Medicine News(10 mins):Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2
... A large, national multi-center study of thousands of children ... has found that most of those with normal computed ... observation. Of the more than 13,500 children included ... abnormal CT scans or MRIs and none required neurosurgical ...
... than white Americans, even when they have some ... is so, researchers at Columbia University,s Mailman School ... Medicine, surveyed African American adults with recent oral ... findings provide insights into why disparities persist even ...
... DALLAS June 16, 2011 UT Southwestern Medical ... anesthetic drug ketamine produces a fast-acting antidepressant response in ... robust effect at low doses as a fast-acting antidepressant ... "Ketamine produces a very sharp increase that ...
... esophagus may have a lower risk of esophageal cancer ... published online June 16 in the Journal of ... a premalignant condition, and patients who have it are ... signs of esophageal adenocarcinoma, the most common kind of ...
... -- The risk of cancer associated with the condition ... thought, according to a new long-term study. ... undergo routine endoscopies to screen for esophageal adenocarcinoma, a ... a long, thin tube with a camera at the ...
... Louis Children,s Hospital in the summer of 2010 near death ... lungs. Washington University physicians and surgeons at St. Louis ... his life. They collaborated to make several strategic and innovative ... artificial lung in a toddler. Their efforts are reported ...
Cached Medicine News:Health News:Hospitalizing children with normal CT scans after blunt head trauma is not necessary 2Health News:Hospitalizing children with normal CT scans after blunt head trauma is not necessary 3Health News:Why disparities in dental care persist for African-Americans even when they have insurance coverage 2Health News:Why disparities in dental care persist for African-Americans even when they have insurance coverage 3Health News:Barrett's esophagus carries lower risk of malignancy than previously reported 2Health News:Cancer Risk With Barrett's Esophagus May Be Lower Than Thought 2Health News:Washington University surgeons successfully use artificial lung in toddler 2Health News:Washington University surgeons successfully use artificial lung in toddler 3Health News:Washington University surgeons successfully use artificial lung in toddler 4
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
(Date:8/29/2014)... Aug. 29, 2014   Vittamed Corporation , a neurodiagnostics ... announced today that T. (Teo) Forcht Dagi , MD, ... Board of Directors. " Teo Forcht Dagi ... neurosurgery, medical innovation and venture capital," said Remis Bistras ... to add his clinical, strategic, and entrepreneurial expertise to our ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Organogenesis, Inc. announced that its Apligraf® bilayered living cellular construct ... and other chronic wounds by the Saudi Food and Drug ... a living cell based product used by physicians to heal ... world. "With diabetes being a widespread and growing ...
... 28 Boston Scientific Corporation (NYSE: BSX ... long-term data from the MADIT II clinical trial in ... demonstrates that the life-saving benefits of implantable cardioverter defibrillator ... the first time that long-term data regarding the benefits ...
Cached Medicine Technology:Apligraf® Approved by Saudi Food and Drug Authority for Treatment of Chronic Wounds 2Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy 2Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy 3
... important part of managing the disease state ... mean delivering the aerosolized medication to the ... medication waste. Aerosol delivery with the Salter ... including the new NebuTech® HDN®, helps to ...
Wire-wave tongs...
Tongs...
... vitro Nucleic Acid Hybridization Assay ... Chemiluminescence for the Qualitative Detection ... 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 and Analysis ... Groups in Cervical Specimens: HPV ...
Medicine Products: